Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Finotonlimab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Finotonlimab is an immunotherapy medicine developed and made in China by Sinocelltech, where it is sold as 安佑平® (An You Ping). It belongs to the PD-1 antibody family, which helps the immune system recognise and attack cancer cells. It is given as a drip every three weeks, always together with other cancer treatment.
China's National Medical Products Administration (NMPA) approved it in February 2025 for two cancers:
It is a prescription cancer medicine and should only be used under a medical oncologist.
T cells, the immune system's fighters, carry a "brake" called PD-1. Many tumours press on this brake to switch the T cells off. Finotonlimab is a humanised IgG4 antibody that sits on PD-1 and blocks the tumour's signal, so the T cells can become active against the cancer again. Sinocelltech notes that its IgG4 design has low ADCC and CDC activity, meaning it is built not to destroy the immune cells it binds to.
Head and neck cancer: the phase 3 trial published in Nature Medicine in 2024 included 370 patients in China. Adding finotonlimab to cisplatin and 5-fluorouracil chemotherapy extended median survival from 10.5 to 14.1 months (hazard ratio 0.73). At one year, 53.5% of patients were alive against 39.4%. Responses also lasted far longer, a median of 19.3 months against 5.0 months. In patients whose tumours had a PD-L1 score (CPS) of 20 or more, median survival reached 20.1 months.
Liver cancer: in a phase 3 trial of 346 patients presented at ASCO 2024, finotonlimab with a bevacizumab biosimilar was compared with a standard tablet treatment. Median survival was 22.1 months against 14.2 months (hazard ratio 0.60), and the time before the cancer grew was 7.1 against 2.9 months. About a third of patients (32.8%) responded, compared with 4.3%.
In both phase 3 trials the dose was:
Chemotherapy is given about an hour after the finotonlimab drip. Your oncologist sets the exact plan and the number of cycles.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Like other PD-1 medicines, finotonlimab can make the immune system attack healthy organs. The figures below are from the head and neck cancer trial, where it was given with chemotherapy.
Overall: severe (grade 3–5) treatment-related side effects occurred in 25.1% of patients on finotonlimab plus chemotherapy and 17.1% on chemotherapy alone, and 3.6% stopped because of side effects. In the liver cancer trial, severe treatment-related side effects occurred in 42.6% of patients on the combination, most often high blood pressure (7.8%), and three deaths from bleeding or unknown causes were linked to the bevacizumab partner. Safety in pregnancy, breastfeeding and children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other cancer immunotherapy medicines we can help import, see our pages on Libtayo and Imjudo.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The pack states that the vials must be stored and transported at 2°C to 8°C, protected from light, never frozen and not shaken hard, so they travel under temperature-controlled shipping all the way to the hospital. Each dose uses two vials, and we plan supply cycle by cycle. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid oncologist's prescription.
Head and neck and liver cancer units here treat patients from all over North India, and our New Delhi dispatch point keeps the cold-chain leg short.
Refrigerated vials are delivered to the hospital pharmacy before each three-weekly infusion day.
Oncologists in Bangalore can request the medicine for a named patient and receive a written quote before anything is ordered.
A leading centre for head and neck cancer care in South India, experienced with imported refrigerated biologics.
We time each delivery to the cycle date so the infusion and chemotherapy can go ahead as planned.
Shipments to Kolkata and the north-east are routed to stay within 2°C to 8°C from dispatch to hospital.
Patients in Pune can use the same documented import route, with updates at every stage.
The treating oncologist can send us the prescription, biopsy report and treatment history to begin the import.
Patients treated at hospitals in Vellore can have each cycle's supply delivered straight to the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with cold-chain delivery to the treating hospital.
We coordinate refrigerated delivery to public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive the medicine at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
